

CORCEPT THERAPEUTICS INC
 Form 3
 April 18, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | |
|---|--|--|---|--|---|
| 1. Name and Address of Reporting Person * LeDoux Anne M (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE (Street) MENLO PARK, CA 94025 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 04/16/2007 | 3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) VP & Controller | 5. If Amendment, Date Original Filed(Month/Day/Year) | 6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |
|---|--|--|---|--|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
|------------------------------------|--|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|--|--|--|
| | Date Exercisable Expiration Date | Title Amount or Number of | | | |

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 3

| | | | | Shares | | or Indirect (I) (Instr. 5) | |
|-----------------------------|-------|------------|--------------|--------|---------|----------------------------------|---|
| Stock Option (right to buy) | Â (1) | 04/16/2014 | Common Stock | 17,500 | \$ 12 | D | Â |
| Stock Option (right to buy) | Â (2) | 10/06/2014 | Common Stock | 42,500 | \$ 7.73 | D | Â |
| Stock option (right to buy) | Â (3) | 09/23/2015 | Common Stock | 15,000 | \$ 5.7 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|----------------------|-------|
| | Director | 10% Owner | Officer | Other |
| LeDoux Anne M C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025 | Â | Â | Â VP & Controller | Â |

Signatures

/s/ Joseph K. Belanoff, CEO of
Corcept Therapeutics Incorporated,
attorney-in-fact

04/18/2007

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable with respect to 20% of the total number of options shares one year after 4/16/2004 and with respect to an additional 1.67% of the total number of option shares on the monthly anniversary of 4/16/2004 each month thereafter.
- (2) Exercisable with respect to 20% of the total number of options shares one year after 10/6/2004 and with respect to an additional 1.67% of the total number of option shares on the monthly anniversary of 10/6/2004 each month thereafter.
- (3) Exercisable with respect to 20% of the total number of options shares one year after 9/23/2005 and with respect to an additional 1.67% of the total number of option shares on the monthly anniversary of 9/23/2005 each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.